c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma
- PMID: 1346789
- PMCID: PMC495801
- DOI: 10.1136/jcp.45.1.16
c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma
Abstract
Aims: To assess c-erbB-2 immunostaining in relation to morphological type of in situ and invasive breast carcinoma.
Methods: Formalin fixed, wax embedded archival tissue was used. Invasive carcinomas comprised 50 infiltrating ductal (NOS); seven medullary, 10 tubular, 15 mucinous and 24 classic invasive lobular. In situ carcinomas comprised 48 ductal (DCIS) and 10 cases of lobular (LCIS). The antibodies used were pAB1 (polyclonal) which stains cell lines that over express the c-erbB-2 oncogene, and ICR 12 (monoclonal) which stains sections of breast carcinoma known to show c-erbB-2 amplification.
Results: Immunostaining consistent with c-erbB-2 overexpression was found in 10 out of 50 cases of infiltrating ductal carcinoma (NOS), one of 24 infiltrating lobular carcinomas and one of seven medullary carcinomas only. Seventy per cent of ICR 12 positive cases of infiltrating ductal carcinoma also had extratumoral DCIS. Forty six per cent of pure DCIS lesions also showed strong membrane staining for c-erbB-2 protein, confined to large cell types.
Conclusions: Immunostaining for c-erb B-2 oncoprotein occurs mainly in large cell DCIS and infiltrating ductal carcinoma NOS, especially those with an extratumoral DCIS component. There is a low incidence in other types of breast cancer, including those associated with a better prognosis. Different biological mechanisms may be responsible for histologically distinct types of breast carcinoma.
Similar articles
-
c-erbB-2 expression in different histological types of invasive breast carcinoma.J Clin Pathol. 1991 Mar;44(3):211-4. doi: 10.1136/jcp.44.3.211. J Clin Pathol. 1991. PMID: 1672872 Free PMC article.
-
Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.Mod Pathol. 1990 Jul;3(4):449-54. Mod Pathol. 1990. PMID: 2170971
-
Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.Int J Cancer. 1988 Dec 15;42(6):842-5. doi: 10.1002/ijc.2910420608. Int J Cancer. 1988. PMID: 2903851
-
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.
-
What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.Pathol Res Pract. 1993 Dec;189(10):1233-52. doi: 10.1016/S0344-0338(11)80853-8. Pathol Res Pract. 1993. PMID: 7910395 Review.
Cited by
-
ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.Breast Cancer Res Treat. 1995 Aug;35(2):201-10. doi: 10.1007/BF00668210. Breast Cancer Res Treat. 1995. PMID: 7647342
-
The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.Carcinogenesis. 2007 Jun;28(6):1269-76. doi: 10.1093/carcin/bgm018. Epub 2007 Jan 27. Carcinogenesis. 2007. PMID: 17259656 Free PMC article.
-
Biological indices in the assessment of breast cancer.Clin Mol Pathol. 1995 Oct;48(5):M221-38. doi: 10.1136/mp.48.5.m221. Clin Mol Pathol. 1995. PMID: 16696013 Free PMC article. No abstract available.
-
Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer.J Surg Res. 2014 May 1;188(1):119-28. doi: 10.1016/j.jss.2013.11.1089. Epub 2013 Nov 22. J Surg Res. 2014. PMID: 24360117 Free PMC article.
-
Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.Breast Cancer Res Treat. 2025 Sep;213(2):273-279. doi: 10.1007/s10549-025-07781-9. Epub 2025 Jul 18. Breast Cancer Res Treat. 2025. PMID: 40679712
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous